home > news > detailed info

CPhI Worldwide Advisory Board returns with five new global experts

CPhI Worldwide

Board helps to steer the overall development of CPhI events and content

Amsterdam, 8th May 2017:CPhI Worldwide, organised by UBM EMEA, announces its Advisory Board for 2017.

The new board features some of the industry’s most experienced and well-respected executives, consultants and experts, and is designed to bring a wealth of experience to help shape the agenda at the eponymous CPhI Worldwide event – taking place this year in Frankfurt, Germany (24-26 October, 2017 at the Messe Frankfurt).

The board also helps navigate improvements to the event’s co-located zones and sessions, as well identifying future opportunities and the industry’s current hot topics.

This year, the advisory board welcomes five new high-profile members: Jim Miller, President of PharmSource; Rita Peters, Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe and BioPharm International; Peter Schmitt, President of Montesino; Claudia Lin, General Manager at AlphaMab; and Kate Kuhrt, Head of GTM Life Sciences, Clarivate Analytics.

Jim Miller joins the board on the back of the internationally renowned industry analysis he provides to global pharma and contract services companies through his consultancy, PharmSource. Mr Miller is one of the most influential and respected experts in bio/pharmaceutical outsourcing, and regularly speaks at pharma events and is a member of several editorial boards.

Another prominent industry analyst to join the board is Kate Kuhrt, a leading authority on the global API and generics markets, and pharma product launches. She has two decades of experience in covering the industry and is a speaker and adviser to some of the world’s largest pharma companies. Her specialities include emerging biopharma segments and rapid growth markets.

Peter Schmitt will be utilizing over 30 years of industry experience to provide invaluable global insights into the packaging sector. In 1996, he founded Montesino Associates, followed in 2000 by Montesino Technologies. Mr. Schmitt will be leveraging his knowledge to offer insights across M&A and industry consolidation, regulatory initiatives such as serialization, track and trace, Type III Drug Master Files, sustainability, OEE, new materials and technology, and the ever-present challenge of cost optimization.

Bringing knowledge from the Chinese R&D industry is Dr. Claudia Lin, General Manager at AlphaMab Co. Ltd – a leading Chinese biotech company known for its excellent R&D capabilities. Prior to AlphaMab, Dr. Lin was Head of Quality for Innovent Biologics in China, where she built the company’s international standard GMP capabilities from the ground up. Over her career, Dr. Lin has demonstrated a passion for women’s leadership in the industry, and is both a mentor and a leading voice on furthering women in senior roles across pharma.

The final new panellist for 2017 is Rita Peters, Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe and BioPharm International, who brings her decade long experience of editing three of the industry’s biggest publications. Ms. Peters is a leading producer of industry thought-leadership and has a wide ranging global knowledge having covered many of the biggest stories, new technology developments and trends of the last 10-years.

These new members will join together with the seven current members of the expert panel Dilip G. Shah, CEO of Vision Consulting; Alan Sheppard, Principal of Global Generics and Biosimilars at QuintilesIMS; Martin Folger, Head of Global CMC Development – Pharmaceuticals at Boehringer Ingelheim Vetmedica GmbH; Nigel Walker, Managing Director of That’s Nice; Roger Bakale, Vice President of CMC and Clinical Supply Chain at Receptos; Jan Ramakers, Owner of Fine Chemical Consulting Group; Will Downie, Senior Vice President of Global Sales & Marketing, Catalent Pharma Solutions.

“CPhI Worldwide has firmly asserted itself as the leading global platform for doing business and finding new opportunities in the worldwide pharmaceutical community. We are really delighted to be able to call upon such a unique mix of industry experts to provide such invaluable insights into hot topics within the industry, alongside an abundance of knowledge and experience. We now look to further enhance the new opportunities and services we bring to our customers”, Orhan Caglayan, Brand Director at UBM EMEA.

For more information on the advisory board’s role at CPhI, please visit

The full list of CPhI Advisory Board members for 2017 is as follows:
  1. Jim Miller, President, PharmSource (NEW)
  2. Claudia Lin, General Manager, AlphaMab (NEW)
  3. Rita Peters, Editorial Director, Pharmaceutical Technology, Pharmaceutical Technology Europe and BioPharm International (NEW)
  4. Peter Schmitt, President, Montesino (NEW)
  5. Kate Kuhrt, Head of GTM Life Sciences, Clarivate Analytics (NEW)
  6. Dilip G. Shah, CEO, Vision Consulting
  7. Alan Sheppard, Principal, Global Generics and Biosimilars at QuintilesIMS
  8. Martin Folger, Head of Global CMC Development – Pharmaceuticals, Boehringer Ingelheim Vetmedica
  9. Nigel Walker, Managing Director, That’s Nice
  10. Roger Bakale, Vice President CMC and Clinical Supply Chain, Receptos
  11. Jan Ramakers, Owner, Fine Chemical Consulting Group
  12. Will Downie, Senior Vice President of Global Sales & Marketing, Catalent Pharma Solutions
Print this page
Send to a friend
News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B


Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

Temperature Controlled Logistics in Biopharmaceuticals USA 2018

24-25 April 2018, Princeton, USA

After an extremely successful first edition, Temperature Controlled Logistics in Biopharmaceuticals is back in Princeton in April 2018!
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement